As Per the Report Published on June 2018 by Geon Technology Inc., this has been Proven that Cell Transfection is Used for Recombinant Protein Production

Synthetic biology is a new era of biology which incorporates the engineering principle to biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics so as to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand of synthetic biology products is increasing worldwide, the use of transfection products is also increasing.        

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-transfection-market

Global transfection market is expected to reach USD 1,927.11 million by 2028 from USD 936.21 million in 2020 growing with the CAGR of 9.6% in the forecast period of 2021 to 2028. The demand for transfection has been increased in both developed and developing countries and the reason behind this is the increasing occurrence of chronic diseases. The transfection market is growing due to growing demand for chimeric genes and biopharmaceuticals' utilization in the production of proteins. The market will grow in the forecast period due to the exploration of emerging markets, strategic initiatives by market players, and increasing government support.            

Increasing occurrence of chronic diseases enhance the demand for the effective treatment options such as gene therapy across the world will drive the market's growth rate

The increasing cases of chronic diseases such as COVID-19 have led to the discovery of effective gene therapy product, which can replace the defective gene with that of the correct gene. Transfection method is widely used for gene therapy, among others. As the demand of effective and accurate treatment is increasing worldwide, the demand of gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy has the potential for chronic disease treatment is also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is a driver for the transfection market growth.

Report Scope and Market Segmentation

Segment Analysis:

Global transfection market is categorized into ten notable segments which are based on type, methods, CRISPR transfection methods, products, organism, types of molecule, application, stage, end user, and distribution channel.

• On the basis of type, the global transfection market is segmented into transient transfection, stable transfection. In 2021, transient transfection segment is expected to dominate the market with 66.2% market share as the high copy number of the transfected genetic material leads to high levels of expressed protein within the period that it exists in the cell. This means the transfected cells can be rapidly concerted to large quantities of protein in 3-7 days from cloned genes. 
• On the basis of methods, the global transfection market is segmented into non-viral methods, viral methods. In 2021, non-viral methods segment is expected to dominate the market with 80.8% market share as the success rates are high and these methods work well for cells cultured on flat dishes. The reagents used in non-viral methods such as lipofectamine and are easily available and inexpensive making them the ideal choice for transfection processes.
• On the basis of CRISPR transfection methods, the global transfection market is segmented into non-viral methods, viral methods. In 2021, non-viral methods segment is expected to dominate the market with 66.1% market share as it provides with the high transfection efficiency and these methods work well for cells cultured on flat dishes.
• On the basis of products, the global transfection market is segmented into reagent & kits, instruments, software. In 2021, reagent & kits segment is expected to dominate the market with 75.5% market share as they are used to enhance the efficacy of transfection process in genetic experiments, allowing for substantial research to be conducted in the fields of applied gene therapies and the synthetic biology.  
• On the basis of organism, the global transfection market is segmented into mammalian cells, plants, fungi, virus, and bacteria. In 2021, mammalian cells segment is expected to dominate the market with 60.7% market share as mammalian cell transfection is a technique commonly used to express exogenous DNA or RNA in a host cell line using many different ways.  
• On the basis of types of molecule, the global transfection market is segmented into plasmid DNA , small interfering RNA (siRNA), proteins, DNA oligonucleotides, ribonucleoprotein complexes (RNPs), others. In 2021, plasmid DNA segment is expected to dominate the market with 40.5% market share as classic transfection technologies have initially been developed for introducing plasmid DNA into cells, and even today it is the most common vector for transfection. 
• On the basis of application, the global transfection market is segmented into in vitro application, in vivo application, bioproduction, others. In 2021, in vitro application segment is expected to dominate the market with 70.0% market share as it involves delivery of cargo molecules (such as nucleic acids – DNA or RNA) into cultured cells which plays a crucial role in research as well as commercial production of molecules.
• On the basis of stage, the global transfection market is segmented into research, preclinical, clinical phases, and commercial. In 2021, research segment is expected to dominate the market with 66.7% market share primarily with the increasing demand for gene expression across synthetic biology industry, agriculture and other applications. The need to enhance the scale of production across the aforementioned application requires research which is augmenting the market for transfection.
• On the basis of end user, the global transfection market is segmented into biopharma, contract research organizations (CROs), contract manufacturing organization/ contract development and manufacturing organization (CMOs/CDMOs), academia, hospitals, clinical labs. In 2021, biopharma segment is expected to dominate the market with 64.2% market share because of the need to improve efficiency & speed for production of desired cells. Biopharma industry utilizes transfection process for academic research as well as commercial production to develop cost effective methods for producing desired proteins to support preclinical and clinical evaluations of potential therapeutics. 

The biopharma segment will dominate the end user segment of the transfection market

The biopharma segment will emerge as the dominating segment end user segment. This is because of the growing number of biopharmaceutical industries in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

• On the basis of distribution channel, the global transfection market is segmented into direct tender, retail sales, others. In 2021, direct tender segment is expected to dominate the market with 84.2% market share as it is the primary source of procurement across end users. Biopharma companies and research groups tend to prefer direct tenders as the more reliable and cost-effective distribution channel.

The direct tender segment will dominate the distribution channel segment of the transfection market

The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research признает следующие компании в качестве участников рынка: Mirus Bio LLC. (США), Promega Corporation (США), Polyplus Transfection (Франция), Bio-Rad Laboratories, Inc. (США), Merck KGaA (Германия), Lonza (Швейцария), MaxCyte, Inc. (США), Altogen Biosystems (США), SBS Genetech (Китай), FUJIFILM Irvine Scientific (США), Avanti Polar Lipids (Великобритания), PerkinElmer chemagen Technologie GmbH (Германия), Cytiva (США), Geno Technology Inc. (США), R&D Systems, Inc. (США), Takara Bio Inc. (Япония), Thermofisher Scientific Inc. (США), Roche Molecular Systems, Inc. (США), QIAGEN (Германия), OriGene Technologies, Inc. (США).

Развитие рынка

• В мае 2019 года компания Altogen Biosystems выпустила GMP-реагент для направленной трансфекции печени для доставки in vivo биомолекул, включающих miRNA, siRNA, mRNA, плазмиду, малые белки ДНК и т. д. Этот продукт улучшил направленную доставку генной и олигонуклеотидной терапии для лечения рака печени. Выпуск этого продукта позволил компании увеличить доход за счет расширения портфеля продуктов для трансфекции.
• В июле 2019 года компания Mirus Bio LLC выпустила новый проверенный на качество продукт — TransIT-VirusGEN SELECT Transfection Reagent, предназначенный для эффективной доставки ДНК с целью производства крупномасштабных и высокотитровых вирусных векторов. Этот реагент способен улучшить доставку ДНК упаковочного и переносящего вектора в адгезивные типы клеток HEK 293 и суспензии ДНК. Запуск этого продукта расширил портфель продуктов компании и увеличил ее доход.

Региональный анализ

Географически в отчете о рынке рассматриваются следующие страны: США, Канада, Мексика в Северной Америке, Германия, Швеция, Польша, Дания, Италия, Великобритания, Франция, Испания, Нидерланды, Бельгия, Швейцария, Турция, Россия, остальные страны Европы в Европе, Япония, Китай, Индия, Южная Корея, Новая Зеландия, Вьетнам, Австралия, Сингапур, Малайзия, Таиланд, Индонезия, Филиппины, остальные страны Азиатско-Тихоокеанского региона (APAC) в Азиатско-Тихоокеанском регионе (APAC), Бразилия, Аргентина, остальные страны Южной Америки как часть Южной Америки, ОАЭ, Саудовская Аравия, Оман, Катар, Кувейт, Южная Африка, остальные страны Ближнего Востока и Африки (MEA) как часть Ближнего Востока и Африки (MEA).

Согласно анализу Data Bridge Market Research:

Северная Америка будет доминирующим регионом на рынке трансфекции в прогнозируемый период 2021–2028 гг.

Северная Америка занимает самую большую долю на мировом рынке трансфекции, а США доминируют в регионе благодаря большому количеству компаний и высокой концентрации внимания на генетических исследованиях и производстве белка.

По оценкам, Азиатско-Тихоокеанский регион станет самым быстрорастущим регионом на рынке трансфекции в прогнозируемый период 2021–2028 гг.

Ожидается, что Азиатско-Тихоокеанский регион будет расти с самыми высокими темпами роста в прогнозируемый период с 2021 по 2028 год из-за увеличения генетических исследований в регионе. Китай лидирует по росту рынка Азиатско-Тихоокеанского региона, и сегмент транзитной трансфекции доминирует в этой стране из-за более высокой экспрессии транзитных генов.    

Влияние COVID -19

Быстрое глобальное распространение этого вируса привело к значительному числу смертельных случаев. Всемирная организация здравоохранения (ВОЗ) объявила COVID-19 глобальной пандемией в марте 2020 года и рекомендовала строгие меры для прекращения распространения заболевания. С тех пор пандемия замедлила рост отрасли здравоохранения и затруднила цепочку поставок. Однако высокий спрос на препараты для трансфекции открыл многочисленные возможности перед производителями препаратов для лечения COVID-19. Кроме того, высокий спрос на вакцины и возможности лечения стимулировал рост фармацевтической и биотехнологической отраслей.

Более подробную информацию о рынке трансфекции можно найти на сайте:  https://www.databridgemarketresearch.com/reports/global-transfection-market